Phathom Pharmaceuticals Inc
NASDAQ:PHAT

  • LAST PRICE
    17.5200
  • TODAY'S CHANGE (%)
    -0.3000 (-1.6835%)
  • Bid / Lots
    17.2800/ 2
  • Ask / Lots
    18.4100/ 2
  • Open / Previous Close
    17.9100 / 17.8200
  • Day Range
    17.1000
    18.1750
  • 52 Week Range
    6.0650
    19.7100
  • Volume
    961,081

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
PHAT
Phathom Pharmaceuticals Inc
1.1B
-3.4x
---
AUTL
Autolus Therapeutics PLC
1.1B
-3.1x
---
TYRA
Tyra Biosciences Inc
1.1B
-13.8x
---
PRAX
Praxis Precision Medicines Inc
1.1B
-5.6x
---
ELVN
Enliven Therapeutics Inc
1.1B
-12.5x
---
CGEM
Cullinan Therapeutics Inc
1.0B
-5.5x
---
As of 2024-09-28

Company Information

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s pipeline product candidate, VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.

Contact Information

Headquarters
100 Campus Drive, Suite 102FLORHAM PARK, NJ, United States 07932
Phone
302-636-5400
Fax
302-636-5454

Executives

Independent Chairman of the Board
Michael Cola
President, Chief Executive Officer, Director
Terrie Curran
Co-Founder, Chief Operating Officer
Azmi Nabulsi
Co-Founder, Director
David Socks
Chief Financial Officer and Business Officer
Molly Henderson

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$1.1B
Revenue (TTM)
$9.9M
Shares Outstanding
59.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.71
EPS
$-5.13
Book Value
$-1.26
P/E Ratio
-3.4x
Price/Sales (TTM)
110.0
Price/Cash Flow (TTM)
---
Operating Margin
-2,548.78%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.